Unknown

Dataset Information

0

CD8+ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival.


ABSTRACT: Objectives:Tumor-infiltrating lymphocytes (TIL), particularly CD8+ TILs in patients with colorectal cancer (CRC), are highly prognostic in the early-disease stages (I-II). In metastatic disease (stage IV; mCRC), their influence is less well defined. It has presumably failed to contain tumor cells to the primary site; however, is this evident? We explored the prognostic impact of TILs at the primary site in patients who presented de novo with mCRC. Methods:Treatment-naïve patients (109) with mCRC were assessed for CD8+ TILs and PD-L1 expression. Microsatellite instability (MSI) was evaluated by IHC for PMS2 and MSH6 proteins and/or by PCR using the Bethesda panel. Results:Microsatellite instability-high tumors had significantly more CD8+ TILs, with no significant survival advantage observed between MSI-H and microsatellite stable (MSS) tumors (12 vs 19 months, P = 0.304). TIL density for all cases had no impact on OS (low: 20 vs high: 13 months, P = 0.426), while PD-L1 of 1% or higher was associated with reduced mean survival (9.6 vs 18.9 months; P = 0.038). MSI-H tumors and associated immune cells had higher PD-L1 expression than in MSS cases. A positive correlation between PD-L1 on immune cells and CD8+ve TILs was found. A subset of MSS tumors had relatively high TILs approximating that of MSI-H tumors. Conclusion:In contrast to early-stage CRC, the immune response in primary tumors of patients with de novo mCRC does not appear to influence survival. A subgroup of MSS tumors was identified with increased TILs/PD-L1 comparable to MSI-H tumors, traditionally not be considered for immune checkpoint blockade and perhaps should be.

SUBMITTER: Millen R 

PROVIDER: S-EPMC7484874 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

CD8<sup>+</sup> tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous <i>de novo</i> metastatic colorectal carcinoma do not track with survival.

Millen Rosemary R   Hendry Shona S   Narasimhan Vignesh V   Abbott Rebecca R   Croxford Matthew M   Gibbs Peter P   Tie Jeanne J   Wong Hui-Li HL   Jones Ian I   Kosmider Suzanne S   Byrne David D   Zalcberg John J   Fox Stephen S   Desai Jayesh J   Visvanathan Kumar K   Ramsay Robert G RG   Tran Ben B  

Clinical & translational immunology 20200717 7


<h4>Objectives</h4>Tumor-infiltrating lymphocytes (TIL), particularly CD8<sup>+</sup> TILs in patients with colorectal cancer (CRC), are highly prognostic in the early-disease stages (I-II). In metastatic disease (stage IV; mCRC), their influence is less well defined. It has presumably failed to contain tumor cells to the primary site; however, is this evident? We explored the prognostic impact of TILs at the primary site in patients who presented <i>de novo</i> with mCRC.<h4>Methods</h4>Treatme  ...[more]

Similar Datasets

| S-EPMC2978753 | biostudies-literature
| S-EPMC7054305 | biostudies-literature
| S-ECPF-GEOD-43260 | biostudies-other
| S-EPMC8026513 | biostudies-literature
| S-EPMC5353918 | biostudies-literature
| S-EPMC9954714 | biostudies-literature
| S-EPMC9599482 | biostudies-literature
| S-EPMC7810375 | biostudies-literature
| S-EPMC5528735 | biostudies-literature
| S-EPMC6738075 | biostudies-literature